Almirall to focus on respiratory and skin diseases
01 Jan 2010
Pharmaceutical group almirall is to focus its r+d investments on new treatments for respiratory diseases such as asthma and chronic obstructive pulmonary disease (copd) and skin problems, particularly psoriasis and skin cancer.
according to almirall's development director pere berga, the company invested nearly eur 100 million in r&d in 2009. the lab also expects to finalize this year clinical trials for eklira, its new drug for copd. in 2009, almirall posted eur 701 million in revenue, with net profit reaching eur 141 million. the group has a team of 550 researchers at its three centers in sant feliu de llobregat, sant just desvern and sant andreu de la barca (barcelona).
source: expansión 25/01/2010
More news and success stories.
17 Mar 2023
Catalonia presented in Brussels its strategy for leading the design of semiconductors in southern Europe
16 Mar 2023
Barcelona's Port Vell embarks on a major transformation fueled by over 86 million euros in investments
09 Mar 2023
Catalonia attracted €6,400M in foreign investment in 2022, the highest figure on record
27 Feb 2023
Catalan companies in the digital economy sector have grown by 15%